Document:

<PAGE>
                                            ***TEXT OMITTED AND FILED SEPARATELY
                                                CONFIDENTIAL TREATMENT REQUESTED

                                                                   Exhibit 10.26

                                                 Fabric & Home Care PS Purchases
                                                        5299 Spring Grove Avenue
                                                          Cincinnati, Ohio 45217

                                SUPPLY AGREEMENT

1.     BUYER:
       The Procter & Gamble Manufacturing Company, 1 Procter & Gamble Plaza,
       Cincinnati, Ohio 45202-3114, USA, on behalf of itself,

       The Procter & Gamble Company, 1 Procter & Gamble Plaza, Cincinnati, Ohio
       45202-3114, USA, on behalf of itself,

       Procter & Gamble International Operations SA, a corporation organized and
       domiciled under the laws of Switzerland, with offices at Geneva Business
       Center, 47 Route de Saint Georges, 1213 Petit Lancy 1, Geneva
       Switzerland, on behalf of itself and the following affiliated companies:
       [...***...]

       P&G Northeast Asia PTE, Ltd. - Japan Branch, 17, Koyo-cho Naka 1-chome,
       Higashinada-ku, Kobe 658-0032 Japan on behalf of itself.

       Hereinafter, each entity identified above and referred to hereinafter as
       Buyer shall be severally liable to Seller only with respect to that
       portion of Material (as defined below) and purchased by such entity as
       evidenced by Releases under this Agreement. The rights and obligations
       between the parties hereto extend between Seller and each respective
       entity. However, any particular entity within the definition of Buyer
       shall only be bound hereunder with respect to that portion of the
       Material (as defined below) purchased by such entity.

2.     SELLER: Genencor International, Inc., 200 Meridian Centre Boulevard,
       Rochester, New York 14618, USA and its affiliates, herein referred to as
       Seller. As used herein, the term `affiliates' means any corporation
       controlled by or under common control with Genencor International, Inc.,
       through greater than seventy five percent (75%) stock ownership, direct
       or indirect.

3.     MATERIAL: Material shall mean Genencor products which are included and
       described in the appropriate Attachment whether delivered as single
       granules, liquid or any other form mutually agreed upon in an executed
       amendment.

       Attachment 4, "Characterization of Detergent Enzyme Materials", sets out
       samples and information to be provided by the Seller to the Buyer, which
       define characterization of Materials for Safety review. Moreover, Seller
       agrees to supply to Buyer, [...***...] and the antisera necessary to
       perform the ELISA assay for these enzymes.

                                                                          Page 1
<PAGE>

                                               *CONFIDENTIAL TREATMENT REQUESTED

4.     QUALITY: Equal to Seller reference sample most recently submitted by
       Seller and found acceptable to Buyer. Suitable for Buyer's use, as
       determined by Buyer, and in strict accordance with Buyer's applicable
       specifications, and such revisions as may be made during the period of
       this Agreement. The product to be produced shall be of merchantable
       quality. [...***...] Seller agrees to make every reasonable effort to
       comply with Buyer's revised specifications. Each revision or change is
       considered accepted by Seller if an exception to it is not received
       within 45 days after Seller receives it. If no exceptions are received,
       Seller is responsible for adherence to the new standards or
       specifications. If Seller is unable to provide materials in accordance
       with the new specifications established by Buyer at the time needed by
       Buyer, and at a price acceptable to both parties, Buyer shall have the
       option of terminating its obligations under this Agreement for the
       Material(s) involved without penalty.

5.     QUANTITY:

       a.     For all Buyer's products introduced commercially by Buyer after
              January 1, 2001, which includes existing Seller's Materials used
              in new applications, the annual volume commitment of Buyer, and
              related terms, shall be mutually agreed in an executed amendment.

       b.     For each Material (as defined in the appropriate Attachment),
              Buyer shall provide a written annual forecast for the current
              calendar year and the following calendar year. Such forecasts
              shall be estimates only and shall not constitute firm quantity
              commitments. Buyer is to update this forecast as appropriate
              during the contract year. Moreover, written notice will be
              submitted regularly for each Buyer location, with release dates
              provided once per month.

       c.     [...***...]

6.     PRICE:

       a.     The price, including currency provisions, for Seller's Material
              under this Agreement shall be set by the Seller as listed in the
              appropriate Attachment.

       b.     Seller warrants that the prices set forth in this Agreement are
              valid under the provisions of the Robinson-Patman (Price
              Discrimination) Act, Canadian Competition Act and all other
              pertinent laws, orders and regulations in applicable geographies.

7.     PAYMENT TERMS :

       As described in the appropriate Attachment.

8.     SHIPMENTS:

       a.  [...***...] This Agreement will apply to any purchases so made. Buyer
           will not accept charges for packaging unless by prior agreement in
           writing. Any warehousing or customs charges incurred as a result of
           lack of or late receipt of correct documents, caused by Seller, will
           be charged to Seller. Similarly charges caused by Buyer shall be for
           account of Buyer.

                                                                          Page 2
<PAGE>

                                               *CONFIDENTIAL TREATMENT REQUESTED

b.     CONSIGNMENT: Buyer and Seller are continuing to implement, by mutual
       agreement in certain locations, provisions for Consignment activities
       related to Material listing in this Agreement. Such terms, after written
       mutual agreement, shall be either included as an attachment to this
       Agreement or executed as one or more separate agreements

9.     MEET OR RELEASE: [...***...] If Seller fails to do so or cannot legally
       do so, and if the facts and circumstances indicate that such better price
       is not the result of changes in applicable currency exchange rates, Buyer
       may purchase from the supplier of the lower total cost materials, and any
       purchases so made shall be held to apply to this Agreement, and the
       obligation of Buyer and Seller shall be reduced accordingly.

10.    FAVORED NATIONS: If, during the life of this Agreement, Seller provides
       materials substantially the same as those listed herein at prices,
       [...***...] lower than the prices then effective under this Agreement,
       said lower price(s) shall apply to all Seller's Materials thereafter
       provided under this Agreement during the period of sale at such lower
       price(s) to others, provided Seller can legally extend such lower
       price(s) to Buyer.

11.      FAILURE TO SUPPLY:

       a.  The parties have entered into negotiations with the mutual goal of
           obtaining one or more contingency or substitute products qualified
           and approved by Buyer for each Material in the Attachments. If,
           during the term of this Agreement, Seller fails to supply any
           qualified Material defined in Paragraph 3 "Material" and the
           corresponding Attachment, without replacing this Material with
           another qualified Material supplied by Seller which is acceptable, at
           the sole discretion of Buyer, for use in Buyer products, Seller will
           arrange for supply to be reestablished over the shortest period of
           time possible, whether this is at a Seller facility or through an
           arrangement with an alternative supplier (such other supplier to be
           approved by Buyer). In the event that Seller cannot supply, Buyer
           shall have the right to arrange for an alternative supplier via a
           supplier reasonably acceptable to Seller, provided, however, that
           Seller's proprietary information shall be safeguarded by an
           appropriate confidential non-disclosure agreement and non-use other
           than for the purpose of its supply agreement with Buyer; provided
           further that Seller shall provide a non-exclusive, royalty-free
           license to such alternative supplier procured by Buyer covering the
           technology and know-how required to produce the Material, including
           but not limited to samples of the Materials and/or the microorganisms
           used to produce the Material, as well as Seller paying any expenses
           for any upcharges associated with Buyer obtaining the alternate
           supplied Material. There is a limit to the annual expenses covered by
           Seller of fifteen percent (15%) per previous twelve (12) months of
           actual purchases in Buyer's Business Category of the affected
           Material(s) within the specific region(s). For an example of this
           limitation, see Attachment 5, "Failure to Supply Example".

       b.  Under the circumstances described above, [...***...] Seller shall not
           collaborate with third parties or sell this Material for use within
           the Application Area (as described in the appropriate Attachment) for
           the term of this Agreement and thereafter Buyer shall grant to Seller
           a non-exclusive, royalty-free license (without the right to
           sublicense non-Affiliates) under all applicable Patent Rights owned
           or exclusively controlled by Buyer necessary to allow Seller to
           collaborate with third parties and sell such Material for use within
           the Field of Agreement. However, in the event that this Material is
           replaced by another Material supplied by Seller, then exclusivity of
           purchase by Buyer shall be maintained for both Materials pursuant to
           the terms of this Agreement herein.

                                                                          Page 3
<PAGE>

                                               *CONFIDENTIAL TREATMENT REQUESTED

12.    ENVIRONMENTAL COMPLIANCE: Seller warrants that all substances provided
       hereunder comply in all respects with the applicable requirements of the
       Canadian Environmental Protection Act, the U.S. Toxic Substances Control
       Act, Regulations under said Acts and all other related legislation.
       Seller warrants that all substances it provides to Buyer will accurately
       correspond to Buyer's specification(s) and that it will notify Buyer in
       advance of any proposed change in the substance(s) specified and supplied
       hereunder which could alter or add to any of the Chemical Abstract
       Service (CAS) number(s) for those substances which are listed in the Raw
       Material Specification(s) cited herein. Any such changes must be mutually
       agreed upon by the Buyer and Seller prior to shipment to Buyer. Seller
       agrees to indemnify and hold harmless Buyer and its affiliates from all
       damages and liability resulting from any breach of the warranties
       included in this Paragraph.

13.    FORCE MAJEURE: Fire, flood, strikes, lock-out, epidemic, explosion,
       accident, shortage of customarily used transportation equipment (or
       suitable substitute), or other causes beyond the reasonable control of
       the parties, which prevent Seller from delivering or Buyer from receiving
       and/or using the commodity(s) covered by this Agreement, shall operate to
       reduce or suspend deliveries during the period required to remove such
       cause. In the event of reduced deliveries by Seller under the provisions
       of this paragraph, Seller shall allocate its available supply of
       commodity(s), component raw materials, and suitable manufacturing
       facilities among purchasers and Seller's divisions, departments, and
       affiliates on such basis that Buyer's percentage reduction will not be
       greater than the overall percentage reduction in total quantity of
       commodity(s), component raw materials and suitable manufacturing
       facilities Seller has available for supply. Any deliveries suspended
       under this paragraph shall be canceled without liability, and the
       Agreement quantity shall be reduced by the quantities so omitted. In the
       event non-availability of raw materials causes Seller to reduce shipments
       to Buyer, Seller agrees to give Buyer the option to provide such raw
       materials to Seller at a price not to exceed market cost. If Buyer
       provides raw materials to Seller at such price, Seller will increase
       deliveries of commodity to Buyer by the amount produced with the raw
       materials supplied by Buyer, up to the quantity specified in the
       Agreement.

14.    CUSTOMS LAW COMPLIANCE: Seller warrants compliance with applicable
       customs laws and related governmental laws and regulations promulgated
       thereunder. Seller agrees to indemnify and save Buyer harmless for any
       liability, cost or expense incurred as a result of Seller's failure to
       comply. For all orders of non-US origin goods, the Buyer will inform
       Seller(s) of the specific destination(s) of the shipment(s) and the
       import regulations and other legal requirements of the country of
       destination which will apply. In the event that the customs authorities
       of the destination country refuse entry of the goods, except for Buyer's
       failure to provide complete and accurate information as described above,
       or where Material is not F.O.B. Delivered Buyer's plant, Buyer's failure
       to obtain the appropriate import license or pay duty, Buyer will not be
       responsible to pay for the same and, if payment has already been made,
       Seller will reimburse Buyer in full. Except for customs problems caused
       by Buyer's failure, Seller shall be responsible for the repatriation of
       the goods at Seller's own cost.

15.    AGREEMENT PRECEDENCE: [...***...] In the event of any conflict between
       this Agreement and any amendments or supplements thereof, the amendments
       or supplements shall take precedence.

16.    PRODUCTION PROCESS CHANGES: Seller shall notify Buyer prior to making any
       significant changes to Materials provided by Seller, to the production
       process, or production equipment and/or location(s) involved in the
       fulfillment of this Agreement and shall obtain Buyer's agreement that
       such changes do not render the products supplied hereunder unsuitable for
       Buyer's use prior to instituting such changes. Each revision or change is
       considered accepted by Buyer if a notice is not received within 30 days
       after Seller mails it, requesting that Buyer and Seller meet as soon as
       possible to determine the most

                                                                          Page 4
<PAGE>

                                               *CONFIDENTIAL TREATMENT REQUESTED

       effective way for Buyer to provide an efficient cost effective Material
       for use in view of the proposed significant changes described above. If
       no exceptions are received, Buyer agrees to the proposed Seller changes.

       [...***...]

17.    REFORMULATION: Should Buyer by reason of product reformulation, process
       change or similar reason, deem it necessary to reduce or discontinue
       purchases of Materials or services covered by this Agreement, Buyer shall
       have the right to reduce or discontinue Seller's shipments hereunder,
       provided that Buyer notifies Seller as soon as it has reasonable
       expectation of such change and further provided any such reduction or
       discontinuance is in the same proportion as applied by Buyer to other
       suppliers, if any, supplying materials or services to Buyer, and provided
       further, that Buyer has given Seller not less than ninety (90) days'
       notice of such reduction or discontinuance. If Buyer needs to reformulate
       in less than ninety (90) days, Seller will make a good faith effort to
       accommodate Buyer's requirements.

18.    SUBCONTRACTING: Seller shall directly provide all materials and services
       related to production of Materials covered by this Agreement. Seller
       shall obtain written authorization from Buyer prior to assigning or
       subcontracting any work or services involved in the manufacture or
       handling of Materials covered by this Agreement, its extensions, or any
       of Buyer's purchase orders referencing this Agreement.

19.    CONFIDENTIALITY: All proprietary technical, experimental, manufacturing
       and/or other information disclosed by the disclosing party to the
       receiving party pursuant to this Agreement or its extension(s) are
       considered by the disclosing party as being highly confidential in
       nature. The receiving party agrees to take all reasonable precaution to
       prevent disclosure to third parties. The receiving party shall hold in
       confidence the disclosing party's interest in specific materials and any
       technical or business information the receiving party may learn, observe
       or otherwise obtain concerning the disclosing party, or of its
       subsidiaries, incident to the receiving party's performance under the
       terms of this Agreement. These restrictions upon disclosure shall cease
       to apply as to any specific portion of said information which is or
       becomes available to the public generally, not due to the fault of the
       receiving party, or upon receipt by the receiving party of the written
       authorization of the disclosing party to make such disclosure.

20.    SECURITY PRECAUTIONS: Both Buyer and Seller agree to take all reasonable
       security precautions concerning proprietary information, including
       information gained via site access, related to product transferred
       hereunder. In particular, both Seller and Buyer shall protect the
       information of the other, using a standard of care which shall at not
       time be less than the standard of care such Party uses to protect its own
       proprietary information of a similar type or value.

21.    FULFILLING PRODUCTION REQUIREMENTS: Should Seller fail (due to causes
       within Seller's control) to meet Buyer's scheduled releases as mutually
       agreed to by both parties, Seller shall take all reasonable steps,
       including but not limited to, working extra hours, shifts, or days to
       fulfill Seller's obligations hereunder. All costs for such effort will be
       at Seller's expense. Further, Seller may use alternate shipping methods
       to expedite delivery to Buyer to meet schedules to which both parties
       agree. In such cases in North America, Seller must receive Buyer's
       approval prior to the use of any carrier other than those on Buyer's
       approved carrier list. Additional shipping costs resulting from such
       expedited deliveries or use of alternate carriers will be at Seller's
       expense.

22.    INDEMNIFICATION:

                                                                          Page 5
<PAGE>

                                               *CONFIDENTIAL TREATMENT REQUESTED

       a.  By acceptance of this Agreement and in consideration thereof, Seller
           agrees that it shall indemnify and hold Buyer, its affiliated
           companies and their respective officers, directors, agents and
           employees (the "Indemnified Party(ies)") harmless against [...***...]

       b.  [...***...]

       c.  Seller warrants title to the Seller Materials and that such Seller
           Materials as manufactured and packaged by or for Seller will conform
           to the raw material specifications as agreed to by the parties.
           Seller warrants further that Seller Materials will be supplied at
           agreed-upon manufacturing and quality standards applicable at the
           time under this Agreement or under a separate agreement between the
           parties, and will be fit for use in household and laundry cleaning
           products for which the parties have agreed and the Seller Materials
           were designed and manufactured.

       d.  Seller specifically agrees to indemnify and hold the Indemnified
           Parties harmless from and against any and all claims, damages
           (excluding consequential damages except as explicitly detailed
           herein), suits, judgments, expenses (including reasonable attorneys'
           fees), losses or liability arising out of: (i) the breach of any
           Seller warranty in this Agreement or any agreement to which it or an
           affiliated company is party supplying Seller Materials; (ii) the
           negligent manufacture of any Seller Materials; (iii) injury or
           alleged injury (including death) to person, property, or environment,
           when brought by individuals, corporations, government or any other
           entity or persons not employed by Buyer, nor a party to this
           Agreement; or (iv) Seller's negligence in the performance of its
           responsibility hereunder or under any other agreement to which it or
           an affiliated company is party supplying Seller Materials, including
           but not limited to, negligence in the handling, processing, marketing
           or disposal of any such Seller Materials or any part thereof.

       e.  By acceptance of this Agreement and in consideration thereof,
           Buyer agrees that it will indemnify and hold Seller harmless
           [...***...]

       f.  Except to the extent caused by or arising out of the negligent or
           willful acts of Seller or out of a Seller Material, Buyer
           specifically agrees to indemnify and hold Seller, its officers,
           directors, agents and employees (and only those entities or persons)
           harmless from and against any and all claims, damages (excluding
           consequential damages except as explicitly detailed below), suits,
           judgments, expenses (including reasonable attorneys' fees), losses or
           liability arising out of (i) the breach of any Buyer warranty in this
           Agreement or any agreement to which it is party supplying Buyer
           Products; (ii) any alleged defect in any Buyer Product; (iii) injury
           or alleged injury (including death) to person, property or
           environment, caused by the negligent or willful acts of Buyer, when
           brought by individuals, corporations, government or any other entity
           or persons not employed by Seller, nor a party to this Agreement; or
           (iv) Buyer's negligence in the performance of its responsibility
           hereunder or under any other agreement to which it is party supplying
           Buyer Products, including but not limited to, negligence in the
           handling, processing, marketing or disposal of any such Buyer
           Products.

                                                                          Page 6
<PAGE>

                                               *CONFIDENTIAL TREATMENT REQUESTED

       g.     Notwithstanding any other provision of this Agreement, the
              aggregate limit of Seller's liability to any P&G company or
              affiliated company listed in Paragraph 1, "Buyer", above for any
              consequential, indirect or similar damages under all sections of
              this Agreement shall not exceed the most current annual revenue
              paid to Seller under this Agreement by such P&G company or
              affiliated company (based upon Buyer's most recently closed fiscal
              year). However if no such annualized revenue number is available
              because the Buyer and Seller have not operated under this
              Agreement for such a period, (i.e. the sales occurred prior to the
              execution of this Agreement), then revenues paid under terms
              analogous to those contained herein above (i.e., the most current
              annual revenue paid for the year encompassing the start of this
              Agreement) shall be the maximum aggregate limit of Seller's
              liability.

23.    PERSONAL INJURY AND PROPERTY DAMAGE LIABILITY IN SELLER OWNED OR
       CONTROLLED MANUFACTURING OR PROCESSING FACILITIES: Seller assumes sole
       responsibility for taking all necessary health and safety precautions,
       including compliance with all applicable local, state, provincial and
       federal regulations, in Seller's processing material under this
       Agreement. These precautions shall include, but not be limited to, such
       things as proper control of ventilation, the wearing of adequate
       protective clothing, and installation and proper utilization of
       appropriate environmental control equipment. Seller agrees to indemnify
       and hold harmless Buyer for all losses, damages and expenses resulting
       from any claim or action for injury to persons or damage to property or
       action by any regulatory agency arising out of, or in any way associated
       with, the design, installation, and/or operation of any formulation,
       packaging, or support equipment (including equipment owned by Seller,
       Buyer or third parties), and/or the production, Seller's processing or
       handling of the material processed hereunder and all raw materials used
       in the processing including, without limitation, injuries to Seller's
       employees involved in these operations caused or contributed to by the
       negligence of those employees or fellow employees. Seller agrees to
       provide minimum [...***...] of commercial liability insurance in support
       of this indemnity.

24.    SELLER BANKRUPTCY: In the event Seller shall be unable to pay its bills
       as they become due in the ordinary course, or if a trustee or receiver of
       any of its property shall be appointed, or if Seller shall make any
       assignment for the benefit of creditors, or if a petition in bankruptcy
       shall be filed by or against Seller, or if Seller shall liquidate its
       business for any reason, Buyer shall have the right to terminate this
       Agreement immediately without further obligation. Seller will make
       available for Buyer's removal any such raw materials, finished product,
       or other of Buyer's property then under Seller's control. Seller further
       agrees not to encumber such materials, finished product or other
       property, as through security liens or pledges, in any way. Buyer's right
       to remove such Material shall have priority over all other claimants.

25.    CHANGE IN SELLER OWNERSHIP: In recognition of the confidentiality
       obligation Seller has assumed hereunder, Seller agrees not to assign or
       transfer its right and obligations hereunder without the express written
       consent of the Buyer. If for any reason Seller decides to sell or
       transfer the manufacturing operation used in the fulfillment of this
       Agreement, Seller shall provide Buyer with at least ninety (90) days'
       advance written notice of its intent to transfer or sell such operation
       and will alternatively: (a) supply to Buyer written agreement to
       guarantee fulfillment of all obligations of Seller hereunder, or (b)
       extend to Buyer an option exercisable within ninety (90) days after the
       date of such notice to sublease the portions of the facility used in
       performance of this Agreement and to lease any and all equipment for the
       purpose of conducting the manufacturing operation by or on behalf of
       Buyer. It is understood that this option does not in any way limit the
       other rights and obligations of the Parties set forth in this Agreement.
       If the above obligations of Seller are not met in any transfer of
       ownership,

                                                                          Page 7
<PAGE>

                                               *CONFIDENTIAL TREATMENT REQUESTED

       Buyer reserves the right to reduce or discontinue purchases under this
       Agreement, or terminate this Agreement, without obligation if any company
       obtains whole or part corporate ownership of Seller.

26.    BREACH OF TERMS: In the event Seller breaches any of the material terms
       of this Agreement or its extension(s), Buyer shall immediately notify
       Seller and allow Seller a reasonable opportunity to cure said breach not
       exceeding fifteen (15) days. If said breach is not remedied within such
       period, as determined by Buyer, Buyer shall then have the right to
       terminate this Agreement immediately without further obligation to
       Seller. Seller will make available for Buyer's removal any such raw
       materials, finished product, or other of Buyer's property then under
       Seller's control. Seller further agrees not to encumber such materials,
       finished products, or other property as through security liens or
       pledges, in any way.

27.    ENVIRONMENTAL INDEMNITY: Seller agrees to comply with all applicable
       federal, state, provincial and/or local environmental laws, ordinances,
       codes, rules, regulations and permits and to handle all raw materials,
       off specification product, excess or scrap materials, waste, and finished
       products in an environmentally safe manner so as to prevent any
       contamination of the structure, soil or ground water in, on, or adjacent
       to the Seller's facility or plant at which Seller performs the work which
       is the subject of this Agreement. Seller agrees to indemnify Buyer, its
       parent, affiliates, subsidiaries, successors, assigns and their
       respective directors, officers, shareholders and employees (Indemnities)
       and save and hold each of them harmless from all liabilities, losses,
       claims, demands, assessments, fines, costs or expenses (including,
       without limitation, reasonable attorneys' and consultants' fees and
       expenses) of every kind, nature or description arising under common law
       or any applicable environmental law resulting from, arising out of or
       relating to any conditions or activities at or involving any facility or
       plant at which Seller performs the work which is the subject of this
       Agreement.

28.    INVOICING: Buyer and Seller agree there are no present discounts for
       prompt payment. [...***...] If the freight bill is not attached, the
       Seller must show on the invoice, in addition to the transportation
       charge, the weight of the shipment, the freight rate charged, the name of
       the carrier, and attach to the invoice a copy of the bill of lading only.
       Buyer may withhold payment of Seller's invoice until the date that this
       condition has been fulfilled and reserves the right to take cash discount
       from this later date. If Buyer requests that goods be shipped "freight
       collect", Buyer shall be responsible for transportation charges. On
       shipments originating in the U.S., the "non-recourse" clause on the bill
       of lading covering the shipment must be signed, and any overcharges which
       may accrue will be for Seller's account.

29.    FDCA COMPLIANCE: Buyer and Seller presently believe this Agreement does
       not relate to the purchase of any food, drug, cosmetic or device, or
       substance, the intended use of which results or may reasonably be
       expected to result, directly or indirectly, in its becoming a component
       or otherwise affecting the characteristics of any food, drug, cosmetic or
       device (including any substance intended for use in producing,
       manufacturing, packing, processing, preparing, treating, packaging,
       transporting, or holding any food, drug, cosmetic or device). However, if
       Seller and Buyer agree upon the use of one of Seller's Material(s) for
       this type of application, Seller shall guarantee that the thing or things
       comprising each shipment or other delivery hereafter made by Seller to
       Buyer, as of the date of such shipment or delivery, is not adulterated or
       misbranded within the meaning of the U.S. Federal Food, Drug and Cosmetic
       Act, as amended, or within the meaning of applicable U.S. State laws or
       Municipal ordinances in which the definitions of adulteration and
       misbranding are substantially the same as those contained in the U.S.
       Act, and not an article which may not, under the provisions of Section
       404 or 505 of the U.S. Act, be introduced into interstate commerce; is of
       a suitable grade and complies with all requirements of the Food and Drugs
       Act of Canada and the Regulations made thereunder, and with the Canadian
       Federal, Provincial and Municipal laws in that regard; and, that if any
       such article is a coal-tar color or contains a

                                                                          Page 8
<PAGE>

                                               *CONFIDENTIAL TREATMENT REQUESTED

       coal-tar color, that said color was manufactured by Seller, and is from a
       batch certified in accordance with the applicable regulations promulgated
       under the U.S. Federal Food, Drug and Cosmetic Act, as amended, and
       Regulations issued under the Food & Drug Act of Canada, as amended, or
       that Seller has in its possession a guaranty to the same effect from the
       manufacturer of said color. Seller agrees to indemnify and save harmless
       Buyer from any claim or action howsoever arising from Seller's failure to
       comply with the terms of this paragraph.

30.    ACCESS FOR BUYER'S REPRESENTATIVE: Seller will permit Buyer's
       representatives access to any area of Seller's manufacturing facilities
       having to do with the fulfillment of this Agreement upon reasonable
       notice by Buyer, mutually agreed times, and execution of appropriate
       security precautions. Should security requirements of other customers of
       Seller create conflict with this right, Buyer shall be so informed and
       compatible scheduling arranged.

31.    EXPIRATION AND TERMINATION:

       a.  At the expiration or termination of this Agreement, Seller shall not
           be required to supply more than [...***...] requirements of any
           qualified product defined in Paragraph 3 "Material" and the
           corresponding Attachment, based on the date of expiration or
           termination notice. If pursuant to this paragraph, Seller, upon the
           express written request of Buyer, holds in inventory (including work
           in process inventory of manufacture estimated [...***...] of
           inventory) more than the quantity of each qualified product defined
           in Paragraph 3, "Material" and the corresponding Attachment,
           corresponding [...***...] at the date of termination or expiration,
           Buyer will purchase in addition such excess amount [...***...] of
           requirements.

       b.  Regardless of whether this Agreement is in force or terminated,
           Seller shall be restricted in its use of the FN Products to that set
           out in Paragraph 3, "Material" and the corresponding Attachment until
           the expiration of such restrictions as provided in all applicable
           Agreements between Seller and Buyer.

32.    GOVERNING LAW AND LANGUAGE: This Agreement and all dealings between the
       parties hereunder shall be governed by the State of Ohio, and all
       applicable Federal laws and the regulations promulgated thereunder that
       may apply. The parties agree that the United Nations Convention on
       International Sale of Goods shall have no force or effect on transactions
       relating to this Agreement. Both parties understand the English language
       and are fully aware of all terms and conditions contained herein.

33.    NORTH AMERICA REGIONAL TERMS AND CONDITIONS: See Attachment 6, "North
       American Regional Terms and Conditions".

                                                                          Page 9
<PAGE>

                                               *CONFIDENTIAL TREATMENT REQUESTED

BUYER AND SELLER ACKNOWLEDGE ACCEPTANCE OF THE TERMS AND CONDITIONS OF THIS
AGREEMENT, INCLUDING THE ATTACHMENTS LISTED BELOW, EFFECTIVE UPON THEIR
AUTHORIZED SIGNATURE BY BUYER AND SELLER BELOW.

<TABLE>
<CAPTION>
         THE  PROCTER  &  GAMBLE
         MANUFACTURING  COMPANY, INC.                                      GENENCOR  INTERNATIONAL,  INC.
--------------------------------------------------------------         ------------------------------------------------------------
<S>                                                                      <C>
                       (BUYER)                                                            (SELLER)

By  /s/ Steve Bishop                                                  By    /s/  Thomas  J. Pekich
    ---------------------------------------------------------               -------------------------------------------------------
                   (Signature)                                                           (Signature)

                  Steve Bishop                                                           Thomas J. Pekich
    ---------------------------------------------------------               ------------------------------------------------------
                   (Name Typed)                                                          (Name Typed)

as     General Manager, NA Fabric Care                                As    Group  Vice  President,   Industrial Chemicals
    ---------------------------------------------------------               ----------------------------------------------------
                             (Title)                                                               (Title)

Date     10/10/01
         --------------------------------------------

                                                                       By    /S/  Philippe Lavielle
                                                                             -------------------------------------------------------
                                                                                                 (Signature)

                                                                                       Philippe Lavielle
                                                                             ------------------------------------------------------
                                                                                                 (Name Typed)

                                                                       as    Vice  President  and  Business  Unit   Manager
                                                                             ----------------------------------------------------
                                                                             Proctor & Gamble
                                                                                                 (Title)

                                                                       Date     10/05/01
                                                                                -------------------------------------------

         PROCTER  &  GAMBLE
         INTERNATIONAL OPERATIONS SA                                   P&G NORTHEAST ASIA PTE, LTD
-----------------------------------------                      --------------------------------------------------------------------
                 (BUYER)                                                               (BUYER)

By  /S/  S. VanStraelen                                                By    /S/  Daniel Rajczak
    ----------------------------------------------------------               ---------------------------------------------------
                         (Signature)                                                           (Signature)

                 S. VanStraelen                                                   Daniel Rajczak
     ---------------------------------------------------------               ---------------------------------------------------
                         (Name Typed)                                                          (Name Typed)

As     Director Purchases                                              General Manager, Northeast Asia Fabric & Home Care
       -------------------------------------------------------         ---------------------------------------------------
                      (Title)                                                               (Title)

Date     17th of October `01                                           Date     Oct. 17, 2001
         -----------------------------------------------------                  ----------------------------------------------------
</TABLE>

                                                                         Page 10
<PAGE>
                                               *CONFIDENTIAL TREATMENT REQUESTED

    THE  PROCTER  &  GAMBLE COMPANY
                      (BUYER)

By  /s/ Steve Bishop
    ----------------------------------------------------------
                         (Signature)

                  Steve Bishop
     ---------------------------------------------------------
                         (Name Typed)

As     General Manager, NA Fabric Care
       -------------------------------------------------------
                             (Title)

Date     10/10/01
         --------------------------------------------

                                                                         Page 11
<PAGE>

                                               *CONFIDENTIAL TREATMENT REQUESTED

LIST OF ATTACHMENTS:

       Paragraph
       Attachment          Attachment  Title              Paragraph Reference
       ----------          -----------------------------------------------------
              1            [...***...]                    3, 5, 6, 7, 11, 31
              2            [...***...]                    3, 5, 6, 7, 11, 31
              3            [...***...]                    3, 5, 6, 7, 11, 31
              4            [...***...]                          3
              5            [...***...]                         11
              6            [...***...]                         33

                                                                         Page 12
<PAGE>

                                               *CONFIDENTIAL TREATMENT REQUESTED

                                  ATTACHMENT 1
                                   [...***...]

MATERIAL: [...***...]
---------

APPLICATION AREA: [...***...]
-----------------

PERIOD: [...***...]
-------

GEOGRAPHY: [...***...]
----------

QUANTITY: [...***...]
----------

EXCLUSIVITY: [...***...]
-----------

PRICE: [...***...]
-----

                                                                         Page 13
<PAGE>

                                               *CONFIDENTIAL TREATMENT REQUESTED

                                  ATTACHMENT 2
                                   [...***...]

MATERIAL: [...***...]
---------

APPLICATION AREA: [...***...]
-----------------

PERIOD: [...***...]
-------

GEOGRAPHY: [...***...]
----------

QUANTITY: [...***...]
----------

EXCLUSIVITY: [...***...]
-----------

PRICE: [...***...]
-----

                                                                         Page 14
<PAGE>

                                               *CONFIDENTIAL TREATMENT REQUESTED

                                  ATTACHMENT 3
                                   [...***...]

SECTION I:

MATERIAL: [...***...]
---------

APPLICATION AREA: [...***...]
-----------------

PERIOD: [...***...]
-------

GEOGRAPHY: [...***...]
----------

QUANTITY: [...***...]
----------

EXCLUSIVITY: [...***...]
-----------

PRICE: [...***...]
-----

SECTION II:

[...***...]

                                                                         Page 15
<PAGE>

                                               *CONFIDENTIAL TREATMENT REQUESTED

                                  ATTACHMENT 4

[...***...]

                                                                         Page 16
<PAGE>

                                               *CONFIDENTIAL TREATMENT REQUESTED

                                  ATTACHMENT 5
[...***...]

                                                                         Page 17
<PAGE>

                                               *CONFIDENTIAL TREATMENT REQUESTED

                                  ATTACHMENT 6

                                   [...***...]

1.0    COMPLIANCE  [...***...]

2.0    MINORITY SUPPLIERS  [...***...]

                                                                         Page 18<PAGE>
                                            ***TEXT OMITTED AND FILED SEPARATELY
                                               *CONFIDENTIAL TREATMENT REQUESTED

                                                                   Exhibit 10.27

                               RESEARCH AGREEMENT

                                   Effective: OCTOBER 4, 2001 ("Effective Date")

         DOW CORNING CORPORATION having a principal place of business at 2200
Salzburg Road, P.O. Box 994 Midland, Michigan 48686-0994 ("DCC") and GENENCOR
INTERNATIONAL, INC. having a principal place of business at 925 Page Mill Road,
Palo Alto, CA 94304-1013 ("GCOR") (collectively referred to herein as the
"Parties") agree as follows:

         WHEREAS, the Parties have signed a certain Memorandum of Understanding
dated [...***...] (the "MOU") whereby the Parties intend to form a pre-eminent
alliance in the Field of Silicon Biotechnology and to negotiate and execute a
definitive Research Agreement reflecting a research and development alliance and
certain licenses in the Silicon Biotechnology Field (the "Definitive
Agreement");

         WHEREAS, the Parties have signed a certain Interim R&D Agreement dated
[...***...] (the "Interim Agreement") pursuant to which the Parties have
undertaken certain interim research prior to the execution of the Definitive
Agreement; and

         WHEREAS, the Parties intend for this Research Agreement to constitute
the Definitive Agreement as defined in, and contemplated by the MOU.

         NOW THEREFORE, the Parties agree as follows:

                                    ARTICLE I
                                   DEFINITIONS

1.1 "Affiliate" shall mean any corporation or other entity that directly, or
indirectly through one or more intermediaries, controls, is controlled by, or is
under common control with the designated party but only for so long as such
relationship exists. Solely for purposes of this Section 1.1, "Control" shall
mean ownership of greater than fifty percent (>50%) of the shares of stock
entitled to vote for directors in the case of a corporation and greater than
fifty percent (>50%) of the interests in profits in the case of a business
entity other than a corporation.

1.2 "Alliance Rights" shall mean any invention or discovery, patentable or
otherwise, and patent rights associated therewith, which arise out of the R&D
Program, and which is first conceived and/or reduced to practice during the R&D
Program Term.

1.3 "Biological Material" shall mean material including strains, genes, vectors,
plasmids, and other DNA sequences or constructs, libraries and the like,
together with any progeny, mutants, derivatives or replicated forms thereof, and
any information relating thereto.

1.4 "Commercial Entity" shall have the meaning set forth in Section 8.1.

<PAGE>

                                               *CONFIDENTIAL TREATMENT REQUESTED

1.5 "Commercial Phase" shall mean the phase of the alliance focused on
commercialization of products developed during the Research Phase.

1.6 "Controlled or Controls" shall mean with respect to any patent rights, the
ability to grant licenses or sublicenses in the Silicon Biotechnology Field to
and/or disclose such without violating the terms of any bona fide agreement with
a Third Party to which such patent right is subject.

1.7 "DCC Background Rights" shall mean all know-how and patent rights owned or
Controlled by DCC as of the Effective Date of this Agreement (excluding any such
rights that are subject to an exclusive license to a Third Party) or developed
by DCC independently during the R&D Program Term and useful for the research,
development and/or commercialization of products or processes in the Silicon
Biotechnology Field.

1.8 "Designated Management Representative" shall in the case of DCC be
[...***...] and in the case of GCOR be [...***...], which representatives shall
be responsible for conflict resolution and decision making which is unresolved
by the Steering Committee.

1.9 "Development Activities" shall mean activities undertaken by either Party on
a R&D Program at the decision of the Steering Committee which activities relate
to the scale up of a product or process which meets certain agreed upon
functional performance criteria and/or cost specifications, such activities to
be at a scale consistent with commercial validation.

1.10 "FTE" shall mean full time equivalent of GCOR research and development
personnel including direct and indirect costs.

1.11 "GCOR Background Rights" shall mean all know-how and patent rights owned or
Controlled by GCOR as of the Effective Date of this Agreement (excluding any
such rights that are subject to an exclusive license to a Third Party) or
developed by GCOR independently during the R&D Program Term and useful for the
research, development and/or commercialization of products or processes in the
Silicon Biotechnology Field.

1.12 "Milestones" shall have the meaning set forth in Section 3.2.

1.13 "Project" shall mean each specific project with its related Work Plan
approved by the Steering Committee for incorporation in the R&D Program.

1.14 "Quarter" shall mean each calendar three (3) month period during the R&D
Program Term as measured from the Effective Date.

1.15 "R&D Program" shall have the meaning set forth in Section 2.4.

1.16 "R&D Program Term" shall have the meaning set forth in Section 10.2.

1.17 "Research Phase" shall mean the phase of the alliance focused primarily on
the R&D Program.

1.18 "Silicon Biotechnology Field" shall mean [...***...].

                                      -2-
<PAGE>

                                               *CONFIDENTIAL TREATMENT REQUESTED

1.19 "Third Party" shall mean any person or persons including any individual
business entity, partnership, corporation, or other entity other than Dow
Corning Corporation and Affiliates or Genencor International, Inc and
Affiliates.

1.20 "Work Plan" shall mean the detailed work plan developed for each Project
within the R&D Program as described in Section 2.4.

                                   ARTICLE II
                      THE RESEARCH AND DEVELOPMENT ALLIANCE

2.1 [...***...] OF ALLIANCE. During the R&D Program Term, except for the
pre-existing relationships of GCOR in the Silicon Biotechnology Field as
disclosed in Exhibit B, [...***...] through the Alliance in the Silicon
Biotechnology Field.

         During the R&D Program Term, except for the pre-existing relationships
of [...***...] in the Silicon Biotechnology Field as disclosed in Exhibit C,
[...***...] will first notify the Alliance in writing of any biotechnology-based
opportunities within the Silicon Biotechnology Field of which [...***...] is or
becomes aware. [...***...]

2.2 SCOPE OF THE ALLIANCE. The initial focus of the Alliance is the research,
development and commercialization of products and processes within the Silicon
Biotechnology Field, however, as appropriate and upon mutual agreement of the
Parties, the Alliance may be expanded to include [...***...].

2.3      STEERING COMMITTEE.

         (a) MEMBERSHIP. A committee (the "Steering Committee") consisting of
         three (3) members appointed by GCOR and three (3) members appointed by
         DCC shall be established in order to monitor and coordinate the
         Alliance efforts under this Agreement including the conduct of the R&D
         Program. Each Party has one (1) vote total on any matter within the
         scope of the R&D Program coming before the Steering Committee. The
         Steering Committee may invite additional representatives from both
         parties to participate in meetings as deemed necessary and appropriate.

         (b) RESPONSIBILITIES. The Steering Committee shall have general
         responsibility, subject to the provisions of Section 2.3(d) below, for
         directing the research and development efforts under the R&D Program
         and for monitoring the work done under the R&D Program. The Steering
         Committee shall in good faith discuss matters related, but not limited
         to:

              (i)    Selecting and prioritizing projects, setting priorities and
                     time frames for the performance of certain activities and
                     deliverables outlined in the agreed Work Plan for each
                     project;
              (ii)   Directing the Alliance's research and development efforts
                     under the R&D Program;
              (iii)  Reviewing progress versus agreed work plans for each
                     project;
              (iv)   Making recommendations on changing, expanding or
                     discontinuing research on project(s);

                                      -3-
<PAGE>

                                               *CONFIDENTIAL TREATMENT REQUESTED

              (v)    Reviewing budgets and funding requirements for each goal or
                     project within the R&D Program subject to the funding
                     obligations set forth in this Agreement;
              (vi)   Resolving possible conflicts of interest;
              (vii)  Recommending inclusion of any third parties or any
                     intellectual property rights or know-how belonging to third
                     parties in the R&D Program;
              (viii) Reviewing personnel requirements for each goal or project
                     within the R&D Program; and
              (ix)   Reviewing progress toward Milestones and making
                     recommendations to pay milestone payments pursuant to the
                     project Work Plans.

         (c) MEETINGS. The Steering Committee shall hold meetings at such times
         and places as shall be determined by a majority of the entire
         membership of the Steering Committee, provided that in no event shall
         such meetings be held less frequently than once every quarter. Such
         meetings may be held in person or by telephone conference, provided
         that any decision made during a telephone conference is evidenced by a
         confirmed writing signed by one or more of the members of the Steering
         Committee from each Party.

         (d) VOTES. Actions to be taken by the Steering Committee pursuant to
         the terms of this Agreement shall only be taken following the unanimous
         vote of the Steering Committee. The Steering Committee shall attempt to
         have all decisions approved by all members of the Steering Committee.
         If the Steering Committee is unable to reach a unanimous decision, such
         matters shall be referred to the Designated Management
         Representative(s) of each Party for consideration and action. While the
         Steering Committee may take actions to coordinate the efforts taken by
         each Party under the R&D Program and to make recommendations concerning
         the matters set forth in Section 2.3(b), the Steering Committee shall
         not have any authority to enter into any contract or to amend the terms
         and condition of this Agreement or incur any liability on behalf of
         either Party but shall be required to refer any such matters to, and
         obtain authorization from, the respective management of each Party.
         Notwithstanding the creation of the Steering Committee, each Party
         shall retain the rights, powers and discretion granted to it under this
         Agreement and such Steering Committee shall not be delegated with any
         such rights, powers or discretion unless the Parties expressly agree in
         writing.

         (e) EXPENSES. Each Party shall bear all expenses of its representatives
         related to the Steering Committee and the attendance at any meetings of
         the Steering Committee.

2.4 RESEARCH AND DEVELOPMENT PROGRAM. Using the Steering Committee as the device
through which agreement is reached, DCC and GCOR will jointly agree on the
research and development work to be performed under this Agreement, including
which Party is responsible for such work, whether it is to be performed jointly
by the Parties or solely by one of the Parties, relevant time lines for progress
of such work and such other factors as are deemed necessary and appropriate to
conduct the work. A summary of the work to be performed under the Agreement,
including the initial R&D Program proposals for [...***...] (the "R&D Program"),
is attached hereto and incorporated in the

                                      -4-
<PAGE>

                                               *CONFIDENTIAL TREATMENT REQUESTED

Agreement as Exhibit D. Detailed Work Plans, including objectives, time lines,
personnel requirements, milestones, performance metrics and deliverables, will
be developed for each Project within the R&D Program. Said Work Plans, when
generated and agreed upon by the Parties, will be incorporated into this
Agreement. Work Plans may be amended by mutual agreement of the Parties and such
amended Work Plans shall be attached hereto and incorporated herein.

2.5      INTERIM RESEARCH AGREEMENT. Upon execution of this Agreement, the
Interim Agreement shall automatically terminate, subject to the Parties rights
and obligations arising from the Interim Research Agreement prior to its
termination.

2.6      FUNDING OF ALLIANCE BY DCC.

         (a) FUNDING. Subject to the terms and conditions set forth herein, DCC
         shall fund GCOR FTE's at a rate of [...***...] as payment for the
         research to be performed by GCOR under the R&D Program ("Research
         Funds"), such funding to be paid in accordance with the terms of
         Section 2.6(b).

         (b) PAYMENT. At the end of each Quarter during the Program Term, GCOR
         will send DCC an invoice for the FTE's expended on the R&D Program
         during the prior Quarter. DCC will pay GCOR the amount invoiced within
         thirty (30) days of receipt of the invoice.

         (c) STAFFING. Staffing levels will be mutually agreed to by the Parties
         and through the operation of the Steering Committee and based on the
         needs of the R&D Program. The overall levels of personnel allocated to
         the R&D Program will be reviewed and adjusted (as appropriate)
         quarterly by the Steering Committee to reflect the needs of the R&D
         Program. Subject to agreement by the Steering Committee to the
         contrary, it is expected that the overall level of personnel allocated
         by GCOR over the [...***...] will be approximately [...***...]
         scientific personnel .

         (d) CONFIRMATION OF STAFFING. GCOR will, at the end of each Quarter,
         provide DCC a report confirming the man-months expended during the
         prior Quarter.

2.7      DCC COSTS. DCC will pay all its own expenses for work on the R&D
Program, with no cost sharing by GCOR.

2.8      DEVELOPMENT COSTS. Each Party will pay its own expenses for Development
Activities on the R&D Program.

2.9      PERFORMANCE. Payment of the Research Funds shall be a condition to
GCOR's obligation to perform the work set out in the R&D Program, and shall be
a basis for termination of this Agreement by GCOR under Section 10.3 if such
payments are not timely made. Subject to adjustments in staffing made by the
Steering Committee, adequate staffing shall be a condition to DCC's obligation
to make payments pursuant to Section 2.6, and shall be a basis for termination
of this Agreement by DCC under Section 10.3 if staffing is not adequately
provided.

2.10     PERFORMANCE OBLIGATIONS. The R&D Program shall be conducted at and/or
coordinated from the facilities of each Party under the direction and
supervision of the

                                      -5-
<PAGE>

                                               *CONFIDENTIAL TREATMENT REQUESTED

Steering Committee. GCOR shall use reasonable commercial efforts to diligently
carry out and perform its tasks and duties under the R&D Program within the time
periods set out in the Work Plan(s). Each Party shall be responsible for the
administrative management and, subject to the funding obligations of DCC under
Section 2.6(a), fiscal control and all other expenses incurred by it for tasks
and duties assigned to it in the R&D Program. So long as the R&D Program
continues, GCOR and DCC shall periodically (at least quarterly) provide to the
Steering Committee progress reports summarizing the technical progress of their
respective work. Notwithstanding any other provision herein, provided GCOR shall
have used reasonable commercial efforts to perform its tasks and duties under
the R&D Program as herein required, GCOR shall not be liable for any failure to
achieve its objectives described in the Work Plan on a timely basis or at all.

                                   ARTICLE III
                                    PAYMENTS

3.1 UPFRONT PAYMENT. Promptly upon execution of the Research Agreement and in
consideration for [...***...] in the Silicon Biotechnology Field through the
Alliance, DCC will pay GCOR a [...***...] lump sum payment of Twelve Million US
Dollars ($12,000,000).

3.2 R&D BASED MILESTONES. Pursuant to the MOU, the Parties have agreed that DCC
will make payments to GCOR of up to [...***...] for achievement of certain
performance milestones ("Milestones"). Upon agreement by the Parties based on
the Steering Committee's review of the scientific data and results of the R&D
Program that a particular Milestone set forth in a Project Work Plan was
achieved, DCC will make the specific non-refundable, lump sum payment(s) to GCOR
associated with the performance milestones. The Milestone(s) that trigger such
lump sum payments will be agreed to through operation of the Steering Committee
for appropriate Project(s) within the R&D Program. The objectives for the
Milestones, timelines or other factors affecting payment and the relevant
payment will be agreed upon and set forth in the Work Plan for each relevant
Project.

3.3 TIMING OF PAYMENT. Promptly, and no later than sixty (60) days after the
Steering Committee determines that a Milestone has been met, DCC shall pay GCOR
the applicable Milestone Payment.

                                      -6-
<PAGE>

                                               *CONFIDENTIAL TREATMENT REQUESTED

                                   ARTICLE IV
                              INTELLECTUAL PROPERTY

4.1 BACKGROUND RIGHTS. GCOR Background Rights shall continue to be owned or
Controlled by GCOR, subject to the licenses granted to DCC pursuant to Section
4.2. DCC Background Rights shall continue to be owned or Controlled by DCC,
subject to the licenses granted to GCOR pursuant to Section 4.3.

4.2 GCOR LICENSE TO DCC. In consideration of the license granted to GCOR
pursuant to Section 4.3, GCOR hereby grants to DCC and DCC accepts a [...***...]
license to GCOR Background Rights for the research, development and
commercialization of products or processes in the Silicon Biotechnology Field.
Periodically and at least annually during the R&D Program Term, GCOR will
identify and list GCOR Background Rights that are deemed to be relevant to the
research, development and commercialization of products or processes in the
Silicon Biotechnology Field or which were specifically utilized by or for the
Alliance during the R&D Program (the "GCOR Listed Rights"). The GCOR Listed
Rights are specifically identified and described in Exhibit E.

4.3 DCC LICENSE TO GCOR. In consideration of the license granted to DCC pursuant
to Section 4.2, DCC hereby grants to GCOR and GCOR accepts a [...***...] license
to DCC Background Rights for the research, development and commercialization of
products or processes in the Silicon Biotechnology Field. Periodically and at
least annually during the R&D Program Term, DCC will identify and list DCC
Background Rights that are deemed to be relevant to the research, development
and commercialization of products or processes in the Silicon Biotechnology
Field or which were specifically utilized by or for the Alliance during the R&D
Program (the "DCC Listed Rights"). The DCC Listed Rights are specifically
identified and described in Exhibit F.

4.4 [...***...] ALLIANCE RIGHTS. All right, title and interest in any inventions
including patent rights relating thereto arising from the R&D Program,
regardless of whether those inventions are made solely by employees or agents of
either DCC or GCOR or jointly by employees or agents of both DCC and GCOR, will
be [...***...] (the "Alliance Rights"). Inventorship shall be determined in
accordance with US Patent Law. To the extent Third Parties are included in the
R&D Program, the Parties will endeavor to obtain ownership of any inventions and
related patent rights associated with inventions made by Third Party employees.
However, in the event the Parties are unable to obtain ownership, they will at a
minimum obtain a license on behalf of both Parties to said inventions and
related patent rights.

4.5 COMMERCIAL RIGHTS TO USE ALLIANCE RIGHTS. Upon formation of the Commercial
Entity, the Alliance Rights will either be exclusively licensed or assigned to
the Commercial Entity by DCC and GCOR. At such time the Parties will mutually
agree whether to license or assign the Alliance Rights to the Commercial Entity
and in the absence of such agreement, the Alliance Rights will be exclusively
licensed to the Commercial Entity.

         Subject to Article X, neither Party will have the right to make, use or
sell products or processes covered by the Alliance Rights nor sublicense the
Alliance Rights within or outside the Silicon Biotechnology Field without the
prior written agreement of the other

                                      -7-
<PAGE>

                                               *CONFIDENTIAL TREATMENT REQUESTED

Party; provided, however, that each Alliance Partner is hereby granted the right
but not the obligation to obtain [...***...]. If a Party desires to obtain such
a [...***...] for use [...***...] Silicon Biotechnology Field the Party so
desiring the license (the "Requesting Party") should provide written notice to
the non-requesting party. Upon receipt of such notice, the Parties shall
negotiate in good faith the terms and conditions of said license, including for
example whether it is [...***...] and the [...***...]. In the absence of
agreement on reasonable terms of said license within ninety (90) days from
notice by the Requesting Party shall be granted a license on default terms as
follows, [...***...]. The appropriate [...***...] will be negotiated by the
Parties taking into consideration such factors as [...***...].

4.6 RECOMMENDATIONS ON [...***...] ALLIANCE RIGHTS. The Steering Committee may
make recommendations to the Parties regarding exploitation of the Alliance
Rights within the Silicon Biotechnology Field [...***...].

4.7 PREPARATION / PROSECUTION OF PATENT APPLICATIONS. All reasonable costs
(excluding internal time and costs) associated with the preparation, filing,
prosecution and maintenance of any patent applications or patents covering
Alliance Rights shall be [...***...]. The Parties through the Steering Committee
will agree whether DCC, GCOR or a jointly agreed upon outside counsel will
prepare, file and prosecute any given patent application taking into
consideration the nature of the invention and the expertise of the Parties
relating to the invention. The Parties shall cooperate in the preparation and
filing of any patent applications, including sharing copies of such intended
filings with adequate time for review and comment by the other Party and the
parties shall have the opportunity to review and comment on substantive matters
with respect to the preparation, filing and prosecution of any Alliance Rights.

4.8 ACQUISITION OF THIRD PARTY INTELLECTUAL PROPERTY. The Parties through the
Steering Committee will mutually agree how and whether to license any
intellectual property owned or controlled by Third Parties which may be
necessary to meet the objectives of the R&D Program of this Agreement.

4.9 NO IMPLIED LICENSE OR RIGHT. No license or right is granted by implication
or otherwise with respect to any patent application or patent except as
specifically set forth herein.

4.10 INFRINGEMENT OF THIRD PARTY PATENTS BY THE PARTIES. Should either Party
become aware of any patent that would be infringed by the Research or
Development Activities undertaken in the R&D Program, or be sued for
infringement thereof, that Party shall notify the other Party promptly in
writing. The Parties shall promptly discuss and decide the best way to abate
such potential infringement or defend such action, proceeding or suit.

4.11 INFRINGEMENT OF PATENT RIGHTS BY THIRD PARTIES. [...***...], in the event
of any infringement of any such Alliance Rights, the Parties will promptly
discuss and decide how to enforce such Alliance Rights against an alleged Third
Party infringer. The Parties will cooperate in any action taken to enforce the
Alliance Rights and will reach agreement on various issues relating to any such
enforcement action including, but not limited to, determining which Party will
lead such enforcement action, and any settlement discussions, cost sharing and
award sharing (if any).

                                      -8-
<PAGE>

                                               *CONFIDENTIAL TREATMENT REQUESTED

                                    ARTICLE V
                                 CONFIDENTIALITY

5.1 CONFIDENTIAL INFORMATION. In consideration of disclosure by either of the
Parties to the other Party of confidential information in written or oral form
or in the form of samples, the recipient and the recipient's Affiliates
undertake for a period of [...***...] years from the termination or expiration
of the R&D Program Term to treat received information as strictly confidential
and therefore not to disclose it to any Third Party (except reliable employees
and Affiliates and sublicensees under similar secrecy obligations), and to make
no commercial use of it except for the purposes of this Agreement or except as
otherwise specifically provided for herein. This obligation does not apply to:

         (a) information which, at the time of disclosure, is already in the
         public domain;

         (b) information which, after disclosure, becomes a part of the public
         domain by publication through no violation of this Agreement;

         (c) information which the recipient is able to prove by competent
         written evidence to have been in the recipient's possession prior to
         any disclosure by the disclosing Party;

         (d) information which is hereafter lawfully disclosed by a third party
         to the recipient, which third party did not acquire the information
         under a still effective obligation of confidentiality to the disclosing
         Party; and

         (e) information which is independently developed by or for a Party
         outside the Silicon Biotechnology Field.

5.2 PRESS RELEASE. The Parties will endeavor to issue a joint press release
after execution of this Agreement. Neither Party shall issue any other public
statement concerning the existence or terms of this Agreement or any activities
related hereto without consulting and agreeing with the other Party. However,
each Party may disclose this Agreement or any activities related hereto without
the other Party's approval if such approval has been requested but not received
within forty-eight (48) hours and such party concludes, after consulting with
its legal advisors, that it is required by law or regulatory or listing agency
to disclose the transaction or part thereof.

                                   ARTICLE VI
                         REPRESENTATIONS AND WARRANTIES

6.1 BY DCC. DCC represents and warrants to GCOR that:

         (a) CORPORATE POWER. As of the Effective Date, DCC is duly organized
         and validly existing under the laws of the State of Michigan and has
         full corporate power and authority to enter into this Agreement and
         carry out the provisions hereof;

                                      -9-
<PAGE>

                                               *CONFIDENTIAL TREATMENT REQUESTED

         (b) DUE AUTHORIZATION. As of the Effective Date, DCC is duly authorized
         to execute and deliver this Agreement and to perform its obligations
         hereunder. The person executing this Agreement on DCC's behalf has been
         duly authorized to do so by all requisite corporate action;

         (c) BINDING AGREEMENT. This Agreement is a legal and valid obligation
         binding upon DCC and enforceable in accordance with its terms. As of
         the Effective Date, the execution, delivery and performance of this
         Agreement by DCC does not to the best of its knowledge conflict with
         any agreement, instrument or understanding, oral or written, to which
         it is a party or by which it may be bound, nor violate any material law
         or regulation of any court, governmental body or administrative or
         other agency having jurisdiction over it;

         (d) TECHNOLOGY OWNERSHIP. DCC owns or Controls the DCC Background
         Rights and has the right to grant to GCOR the [...***...] granted under
         Section 4.2 hereof and that said license does not conflict with or
         violate the terms of any agreement between DCC and any Third Party;

         (e) PRIOR AGREEMENT. Except as set forth on Exhibit C, as of the
         Effective Date, DCC [...***...];

6.2      BY GCOR. GCOR represents and warrants to DCC that:

         (a) CORPORATE POWER. As of the Effective Date, GCOR is duly organized
         and validly existing under the laws of the State of Delaware and has
         full corporate power and authority to enter into this Agreement and
         carry out the provisions hereof;

         (b) DUE AUTHORIZATION. As of the Effective Date, GCOR is duly
         authorized to execute and deliver this Agreement and to perform its
         obligations hereunder. The person executing this Agreement on GCOR's
         behalf has been duly authorized to do so by all requisite corporate
         action;

         (c) BINDING AGREEMENT. This Agreement is a legal and valid obligation
         binding upon GCOR and enforceable in accordance with its terms. As of
         the Effective Date, the execution, delivery and performance of this
         Agreement by GCOR does not to the best of its knowledge conflict with
         any agreement, instrument or understanding, oral or written, to which
         it is a party or by which it may be bound, nor violate any material law
         or regulation of any court, governmental body or administrative or
         other agency having jurisdiction over it;

         (d) TECHNOLOGY OWNERSHIP. GCOR owns or Controls the GCOR Background
         Rights and has the right to grant to DCC [...***...] granted under
         Section 4.2 hereof and that said license does not conflict with or
         violate the terms of any agreement between GCOR and any Third Party;
         and

         (e) PRIOR AGREEMENT. Except as set forth on Exhibit B, as of the
         Effective Date, GCOR [...***...].

6.3      DISCLAIMER. NEITHER PARTY GUARANTEES THE SAFETY OR USEFULNESS OF ANY
PRODUCT. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT

                                      -10-
<PAGE>

                                               *CONFIDENTIAL TREATMENT REQUESTED

NEITHER PARTY MAKES ANY REPRESENTATION OR WARRANTY TO THE OTHER PARTY OF ANY
NATURE, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, ANY WARRANTY OF
NONINFRINGEMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE.

                                   ARTICLE VII
                                 INDEMNIFICATION

7.1      BY DCC. DCC shall defend, indemnify and hold GCOR harmless against any
liability, damage, loss, cost or expense, including legal fees arising out of or
resulting from: (i) DCC's breach of a material term of this Agreement; and (ii)
DCC's breach of any representation or warranty set forth in Section 6.1.

7.2      BY GCOR. GCOR shall defend, indemnify and hold DCC harmless against any
liability, damage, loss, cost or expense, including legal fees arising out of or
resulting from: (i) GCOR's breach of a material term of this Agreement; and (ii)
GCOR's breach of a representation or warranty set forth in Section 6.2.

7.3      NOTICE AND COOPERATION. If either party hereunder receives notice of
any claim or of the commencement of any action, administrative or legal
proceeding, or investigation as to which the indemnity provided for in Article
VII hereof may apply:

         (a) The party seeking indemnification shall notify the indemnifying
         party of such fact within 14 days at the address noted in Section 11.7;
         provided that the failure to so notify shall not release an
         indemnifying party of its obligation hereunder unless such failure
         shall be materially detrimental to the defense of any such action,
         proceeding or investigation; and

         (b) The party seeking indemnification shall cooperate with and assist
         the indemnifying party and its representatives in the investigation and
         defense of any claim and/or suit for which indemnification is provided.

7.4      DEFENSE AND SETTLEMENT. The indemnifying party shall control the
defense of any claim and/or suit for which indemnification is provided under
this Article VII. This agreement of indemnity shall not be valid as to any
settlement of a claim or suit or offer of settlement or compromise without the
prior written approval of the indemnifying party.

                                  ARTICLE VIII
                                COMMERCIALIZATION

8.1      COMMERCIAL PHASE. Prior to commercialization of a product developed by
the Alliance, the Parties will determine the appropriate mechanism for
commercialization taking into consideration business, technical, legal, tax and
financial matters with a guiding principle that the Parties will share equally
in the value created by the Alliance through a joint venture corporation or
partnership (the "Commercial Entity"). The Parties [...***...] that the
Commercial Entity will be owned [...***...] by GCOR and [...***...] by DCC
under the assumption that the Parties' [...***...]; provided, however,
[...***...], the provisions of Section 8.3 hereof will govern. The decision by
the Parties regarding whether to form the Commercial Entity will be triggered
[...***...]. It is anticipated that the

                                      -11-
<PAGE>

                                               *CONFIDENTIAL TREATMENT REQUESTED

formation of the Commercial Entity will occur within [...***...] from the
Effective Date of this Agreement. However, if at the end of the [...***...] the
Commercial Entity has not been formed and this Agreement has not been
terminated, the Parties will agree on an appropriate mechanism to continue
funding of the research and development of products and processes in the Silicon
Biotechnology Field through the Alliance.

8.2      BUSINESS-TO-BUSINESS PRODUCT OPPORTUNITIES. Notwithstanding the
possibility of the Commercial Entity, the Parties recognize that multiple
product opportunities and businesses may arise from the Alliance and
[...***...]. At any time during the existence of the Alliance, the Parties
should discuss and agree on the appropriate vehicle(s) for addressing product
opportunities that arise from the Alliance on a case-by-case basis.

8.3      [...***...] MECHANISM. Based on the current understanding of
[...***...]. At the expiration of the Research Phase and prior to commencement
of the Commercial Phase and the formation of the Commercial Entity, the Parties
will determine [...***...]. Contributions by either Party that are intended to
be included for purposes of this Section 8.3 are [...***...].

         At such time the Parties may [...***...] in the Commercial Entity by
each Party, respectively. Alternatively, the Parties may consider other
mechanisms to account [...***...], including but not limited to, [...***...].
These and other alternatives may be considered by the Parties and their tax,
accounting, and legal advisors, taking into consideration the facts and
circumstances applicable to the Parties at the time.

                                   ARTICLE IX
                               SCIENTIST EXCHANGE

9.1      As part of the R&D Program, the Parties may request to have employees
of either Party visit the other Party as visiting scientists in order to work on
the R&D Program. In accordance with a request received by a Party (the
"Requesting Party") the other Party (the "Hosting Party") will make all
reasonable efforts to accommodate any such reasonable request. All costs for
such visiting scientists will be borne by the Requesting Party.

         A visiting scientist may be present and perform research activities in
Hosting Parties' facilities AT HIS/HER OWN RISK. In no event shall the Hosting
Party be held liable for any injury, harm, or death incurred by a visiting
scientist.

         Any research, development, discovery, or invention performed or made by
a visiting scientist during the term of his/her visiting scientist role,
including any patent or other intellectual property rights relating thereto,
shall be owned in accordance with Article IV of this Agreement.

         If, in the course of a visiting scientist role hereunder, a visiting
scientist receives proprietary information of GCOR or DCC relating to research,
development, business operations, equipment or products of either Party, such
information shall be subject to Article V hereof as GCOR Confidential
Information or DCC Confidential Information, respectively, regardless of whether
its receipt is confirmed in writing.

                                      -12-
<PAGE>

                                               *CONFIDENTIAL TREATMENT REQUESTED

         Nothing herein shall entitle any visiting scientist to, or render
him/her eligible to, participate in any benefits or privileges extended to GCOR
or its employees or DCC or its employees. The Parties may request any visiting
scientist to sign appropriate agreements or disclaimers as deemed necessary by
the Hosting Party

                                    ARTICLE X
                              TERM AND TERMINATION

10.1     TERM OF THE AGREEMENT. This Agreement, unless terminated sooner as
provided herein shall expire at the expiration or termination of the R&D
Program Term.

10.2     TERM OF THE R&D PROGRAM. The R&D Program shall begin on the Effective
Date and continue for a term of two (2) years (the "Initial Term") which term
will extend on a [...***...] by mutual agreement of the Parties (the "Extended
Term").

10.3     MATERIAL BREACH. In the event that either Party breaches any material
provision of this Agreement, the non-breaching Party upon sixty (60) days'
written notice to the breaching Party may terminate this Agreement. However, if
such breach is corrected within the sixty (60) day period and there are no
unreimbursed damages resulting from the breach, the Agreement shall continue in
force.

10.4     TERMINATION BY DCC. DCC may terminate the R&D Program and this
Agreement by providing sixty (60) day prior written notice to GCOR at the end
of the Initial Term or at the [...***...] during the Extended Term.

10.5     TERMINATION BY GCOR. GCOR may terminate the R&D Program and this
Agreement by providing sixty (60) day prior written notice to DCC at the end of
the Initial Term or at the [...***...] during the Extended Term.

10.6     MUTUAL TERMINATION. The Parties m ay mutually agree to terminate the
R&D Program and the Agreement at the end of the Initial Term or anytime during
the Extended Term.

10.7     EFFECT OF TERMINATION.

         (a) TERMINATION BY DCC.

                  (i)  If DCC terminates the R&D Program and this Agreement,
                       pursuant to Section 10.3, then [...***...].

                  (ii) If DCC terminates the R&D Program and this Agreement
                       pursuant to Section 10.4 [...***...], then the
                       [...***...] up license granted by DCC to GCOR in DCC
                       Background Rights for use in the research, development
                       and commercialization of products and processes in the
                       Silicon Biotechnology Field pursuant to Section 4.3
                       [...***...] as follows.
                       a.    Said license [...***...] up to a cap [...***...]
                             after termination (the "Amended License"). The
                             royalty will be agreed to by the Parties taking
                             into consideration the relative contribution of
                             the [...***...] to the commercial product, and
                             such other factors as are reasonably considered in
                             similar transactions.

                                      -13-
<PAGE>
                                               *CONFIDENTIAL TREATMENT REQUESTED

                        b.    The Amended License shall continue for a period of
                              [...***...] from the date of termination.

                  Additionally, the [...***...] license granted by GCOR to DCC
                  in GCOR Background Rights for use in the research, development
                  and commercialization of products and processes in the Silicon
                  Biotechnology Field pursuant to Section 4.2 [...***...]. The
                  Parties will continue to own all Alliance Rights [...***...].

         (b) TERMINATION BY GCOR.

                  (i)  If GCOR terminates the R&D Program and this Agreement,
                       pursuant to Section 10.3, then DCC's license in GCOR's
                       Background Rights [...***...].
                  (ii) If GCOR terminates the R&D Program and this Agreement
                       pursuant to Section 10.5 and prior to the formation of
                       the Commercial Entity, then the [...***...] license
                       granted by GCOR to DCC in GCOR Background Rights for use
                       in the research, development and commercialization of
                       products in the Silicon Biotechnology Field pursuant to
                       Section 4.2 will continue for a period of [...***...]
                       from the date of termination.

                  Additionally, the [...***...] license granted by DCC to GCOR
                  in DCC Background Rights for use in the research, development
                  and commercialization of products in the Silicon Biotechnology
                  Field pursuant to Section 4.3 [...***...]. [...***...] of
                  products or processes made, used or sold employing the
                  Alliance Rights. The [...***...] taking into consideration the
                  relative contribution of the Alliance Rights to the commercial
                  product and such other factors as are reasonably considered in
                  similar transaction.

                  Additionally, [...***...] from entering a relationship with a
                  Third Party in the Silicon Biotechnology Field for a period of
                  [...***...] from the date of termination.

         (c)      MUTUAL TERMINATION. In the event the Alliance Partners
                  mutually agree to terminate the R&D Program and this Agreement
                  pursuant to Section 10.6 [...***...], the [...***...] up
                  license granted by each Party to the other Party in its
                  respective Background Rights will be amended to provide that
                  the license [...***...]. This amended license will continue
                  for a period of [...***...] from the date of termination. The
                  Parties will continue to [...***...].

                  Additionally, [...***...] from entering a relationship with
                  a Third Party in the Silicon Biotechnology Field for a period
                  of [...***...] from the date of mutual termination.

                                      -14-
<PAGE>

                                               *CONFIDENTIAL TREATMENT REQUESTED

                                   ARTICLE XI
                                  MISCELLANEOUS

11.1 FORCE MAJEURE. Each of the Parties hereto shall be excused from the
performance of its obligations hereunder and shall not be liable for damages to
the other in the event that such performance is prevented by circumstances
beyond its effective control. Such excuse from performance shall continue for as
long as the condition responsible for such excuse continues and for a period of
thirty (30) days thereafter, provided that if such excuse continues for a period
of one hundred and eighty (180) days, the Party whose performance is not being
prevented shall be entitled to withdraw from this Agreement. For the purpose of
this Agreement circumstances beyond the effective control of the Party which
excuse said Party from performance shall include, without limitation, acts of
God, enactments, regulations or laws of any government, injunctions or judgment
of any court, war, civil commotion, destruction of facility or materials by
fire, earthquake, storm or other casualty, labor disturbances and failure of
public utilities or common carrier.

11.2 INDEPENDENT CONTRACTORS. Nothing in this Agreement is intended or shall be
deemed to constitute a partnership, agency, employment or joint venture
relationship between the Parties. All activities by the Parties hereunder shall
be performed by the Parties as independent parties. Neither Party shall incur
any debts or make any commitment for or on behalf of the other Party except to
the extent, if at all, specifically provided herein or subsequently agreed upon.

11.3 LIMITATION ON ASSIGNMENT. Except as provided herein, neither Party may
assign this Agreement nor any interest or obligation hereunder except with the
prior written consent of the other, which consent shall not be unreasonably or
untimely withheld. Either Party may assign this Agreement in connection with the
sale or transfer of all or substantially all of its business to which this
Agreement relates. Any permitted assignee shall assume all of the obligations of
its assignor under this Agreement.

11.4 AMENDMENTS OF AGREEMENT. This Agreement may be amended or modified or one
or more provisions hereof waived only by a written instrument signed by both
Parties.

11.5 SEVERABILITY. In the event that any one or more of the provisions of this
Agreement should for any reason be held by any court or authority having
jurisdiction over this Agreement and the Parties to be invalid, illegal or
unenforceable, such provisions shall be deleted in such jurisdiction; elsewhere
this Agreement shall not be affected.

11.6 ARTICLE HEADINGS. The section headings contained in this Agreement are for
convenience only and are to be of no force or effect in construing and
interpreting this Agreement.

11.7 NOTICES. Any notice, report, request, approval, payment, consent or other
communication required or permitted to be given under this Agreement shall be in
writing and shall for all purposes be deemed to be fully given and received, if
delivered in person or sent by registered mail, postage prepaid or by facsimile
transmission to the respective parties at the following addresses:

                                      -15-
<PAGE>

                                               *CONFIDENTIAL TREATMENT REQUESTED

                  If to DCC:                Dow Corning Corporation
                                            2200 W. Salzburg Road
                                            P.O. Box 994
                                            Midland, Michigan 48686-0994
                                            Telefax:  989-496-5956
                                            Attention: [...***...]
                                            Business Manager

                  If to GCOR:               Genencor International, Inc.
                                            925 Page Mill Road
                                            Palo Alto, CA 94304
                                            Telefax:  650-845-6504
                                            Attention:  General Counsel

Either Party may change its address for the purpose of this Agreement by giving
the other Party written notice of its new address.

11.8 NON-WAIVER FOR FAILURE TO ENFORCE COMPLIANCE. The express or implied waiver
by either Party of a breach of any provision of this Agreement shall not
constitute a continuing waiver of other breaches of the same or other provisions
of this Agreement.

11.9 APPLICABLE LAW. This Agreement shall be construed and interpreted in
accordance with the laws of the State of Delaware.

11.10 AUTHORITY TO SIGN; COUNTERPARTS. Each person signing below and each Party
on whose behalf such person executes this Agreement warrants that he, she or it
as the case may be, has the authority to enter into this Agreement. This
Agreement may be executed in one or more counterparts, each of which is an
original but all of which, taken together, shall constitute one and the same
instrument.

                                   ARTICLE XII
                        PROVISION OF BIOLOGICAL MATERIALS

12.1 MATERIAL TRANSFER. Biological Material made available to a party
("Receiving Party") by the other party ("Delivering Party") is made available
for research purposes within the R&D Program only and shall not be used for any
other purpose without the prior written consent of the Delivering Party.
Biological Material provided hereunder will not be used for experiments in which
human beings are subjected to the Biological Material, nor for research purposes
other than the R&D Program, for Third Parties, nor will Biological Material be
transferred to any party outside the Receiving Party without the prior written
consent of the Delivering Party. The Receiving Party obtains no rights or
license in the transferred Biological Material nor may the Receiving Party file
any patent applications claiming such Biological Material. The Receiving Party
will handle such Biological Material in compliance with all laws, regulations
and guidelines applicable to the Biological Material and its use. The Biological
Material is experimental in nature, and is provided AS IS without any warranties
with respect to performance or fitness for particular purpose, or to
completeness and accuracy of information accompanying the Biological Material.
The Receiving Party acknowledges that the Biological Material is provided AS IS
and without any representation or warranty, express or implied unless otherwise
agreed by the Parties.

                                      -16-
<PAGE>

                                               *CONFIDENTIAL TREATMENT REQUESTED

                  IN WITNESS WHEREOF, this Research Agreement has been entered
into on the last date signed by the Parties below.

                                     DOW CORNING CORPORATION

Date:  10/4/01                       By:  /s/ James W. White
       --------------------               -------------------------------------
                                     Name:  James W. White
                                            -----------------------------------
                                     Title:   Executive Director, Science and
                                              Technology

                                     GENENCOR INTERNATIONAL, INC.

Date:  10/4/01                       By:  /s/ Thomas J. Pekich
       --------------------               --------------------------------------
                                     Name:  Thomas J. Pekich
                                          --------------------------------------
                                     Title:    Group Vice President, Bioproducts
                                           -------------------------------------

                                      -17-
<PAGE>

                                               *CONFIDENTIAL TREATMENT REQUESTED

                                    EXHIBIT A

[...***...]

                                      -18-
<PAGE>

                                               *CONFIDENTIAL TREATMENT REQUESTED

                                    EXHIBIT B

                  Section 2.1 GCOR pre-existing relationships:

                                   [...***...]

                                      -19-
<PAGE>

                                               *CONFIDENTIAL TREATMENT REQUESTED

                                    EXHIBIT C

                   Section 2.1 DCC pre-existing relationships:

                             to be added by addendum

                                      -20-
<PAGE>

                                               *CONFIDENTIAL TREATMENT REQUESTED

                                    EXHIBIT D

[...***...]

                                      -21-
<PAGE>

                                               *CONFIDENTIAL TREATMENT REQUESTED

                                    EXHIBIT E

                               GCOR Listed Rights

                             to be added by addendum

                                      -22-
<PAGE>

                                               *CONFIDENTIAL TREATMENT REQUESTED

                                    EXHIBIT F

                                DCC Listed Rights

                             to be added by addendum

                                      -23-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00036-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00036-of-00352.parquet"}]]